GlassScriptPhysician profile
Shivangi Patel
NPI 1740843317
$5,491.02
in general payments reported to CMS, 2019-2025
26 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.37 · 2023: $2,104 · 2024: $1,713 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,448.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $866.51 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $812.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $563.39 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $449.38 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $305.19 | 2023-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $263.39 | 2023-2025 | |
| Amgen INC. | $170.22 | 2023-2024 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.78 | 2023-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $134.01 | 2023-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $83.05 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $76.86 | 2023-2025 | Belsomra, Steglatro, Gardasil 9 |
| Abbott Laboratories | $75.62 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corium, LLC | $67.77 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.31 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $55.97 | 2022-2023 | Rexulti |
| Renalytix Ai, INC. | $53.60 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $47.85 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $46.30 | 2024-2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.43 | 2023 | |
| Idorsia Pharmaceuticals US INC | $42.36 | 2023 | Quviviq |
| Indivior INC. | $41.78 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $37.98 | 2023 | Auvelity |
| Pfizer INC. | $36.37 | 2024 | |
| Viatris Specialty LLC | $18.59 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $13.96 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivangi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.